How much of the weight lost on a GLP-1 drug is muscle?

In the SURMOUNT-1 DXA substudy of 160 people who completed 72 weeks, roughly 75% of the weight lost on tirzepatide was fat and about 25% was lean mass. The placebo group showed the same fat-to-lean ratio, which suggests the split reflects weight loss itself rather than something specific to the drug.

Does losing lean mass on a GLP-1 drug make you weaker?

Not automatically. In the SEMALEAN study of 106 people with severe obesity, lean mass fell about 3 kg by 7 months and then stabilized, while handgrip strength rose by 4.5 kg at 12 months and the share of participants meeting criteria for sarcopenic obesity fell from 49% to 33%. Lean mass and muscle function are different measurements, and they do not always move together.

How much protein should you eat on a GLP-1 drug?

There is no single FDA-set number. The 2025 joint advisory from The Obesity Society, the American College of Lifestyle Medicine, the American Society for Nutrition, and the Obesity Medicine Association lists adequate protein intake and strength training as one of its eight priorities for people on GLP-1 therapy. Because these drugs sharply reduce how much you eat, a dietitian can set a target for your body size and check that you are hitting it.

Is there a drug that prevents muscle loss on GLP-1 therapy?

Not an approved one. In the phase 2b BELIEVE trial presented at the American Diabetes Association meeting in June 2025, adding the investigational antibody bimagrumab to semaglutide produced 22.1% weight loss at 72 weeks with 92.8% of that loss coming from fat, versus 71.8% for semaglutide alone. Bimagrumab is not FDA approved and remains investigational.

Do GLP-1 Drugs Cause Muscle Loss?

The short answer: yes, some of the weight lost on a GLP-1 drug is lean mass, and the trial scans confirm it. In the SURMOUNT-1 body-composition substudy, about 75% of the weight lost on tirzepatide was fat and about 25% was lean mass. The important detail is that the placebo group in the same substudy lost weight in the same 75/25 proportion. That points to weight loss itself, not the drug, as the driver. Protein intake and resistance training are the two levers with real evidence behind them.

"Muscle loss" has become the standard criticism of GLP-1 drugs, and it is worth taking seriously. But the headlines usually skip what the scans actually measured. Here is the data.

How Much of the Weight You Lose Is Muscle?

Two phase 3 trials ran DXA scans on a subset of participants, which is the only way to separate fat from lean tissue on a scale reading.

Tirzepatide: the SURMOUNT-1 substudy

The SURMOUNT-1 DXA substudy enrolled 255 people, of whom 160 had usable scans at both baseline and week 72. On tirzepatide, total fat mass fell 33.9% and lean mass fell 10.9%. Of the total body weight lost, roughly 75% was fat mass and 25% was lean mass. Crucially, the placebo group showed the same ratio (Look et al., Diabetes, Obesity and Metabolism, 2025).

Semaglutide: the STEP 1 substudy

The STEP 1 trial ran a DXA substudy in 140 participants (95 on semaglutide, 45 on placebo). Total fat mass fell 19.3% and visceral fat fell 27.4%. Lean body mass fell in absolute terms, but because fat fell faster, lean mass rose as a share of total body mass, by about 3 percentage points (Wilding et al., New England Journal of Medicine, 2021).

A systematic review and network meta-analysis of GLP-1 and dual-agonist trials put the average lean mass reduction at roughly 25% of total weight lost across the drug class (Neeland et al., Diabetes, Obesity and Metabolism, 2024).

Is That Different From Any Other Weight Loss?

Largely, no. This is the single most misunderstood point in the debate.

Any time you lose a significant amount of body weight, some of it is lean tissue. It is not only muscle: "lean mass" on a DXA scan includes organ tissue, connective tissue, blood volume, glycogen, and the water bound to glycogen. A body carrying 40 kg less does not need the same amount of supporting structure. Studies of diet-only weight loss and of bariatric surgery show lean mass losses in the same 20% to 30% range.

The SURMOUNT-1 finding that placebo and tirzepatide produced the same fat-to-lean split is the strongest available evidence that the drug is not doing something unusual to muscle. It is doing something unusual to the amount of weight lost.

Does Less Lean Mass Mean Weaker Muscles?

Mass and function are separate measurements, and the newest data separates them cleanly.

The SEMALEAN study followed 106 people with severe obesity (mean BMI 46.3) on semaglutide for a year, with DXA scans and physical testing. Weight fell 10% at 7 months and 13% at 12 months. Lean mass dropped about 3 kg by month 7, then stabilized. Meanwhile handgrip strength improved by 4.5 kg at 12 months, and the share of participants who met criteria for sarcopenic obesity fell from 49% at baseline to 33% at one year (Alissou et al., Diabetes, Obesity and Metabolism, 2026).

That result is easy to explain once you separate the two ideas. Carrying less body weight makes you functionally stronger relative to your size, and the fat infiltrating muscle tissue in obesity is itself a driver of weakness. Losing lean kilograms while getting stronger is not a contradiction.

Do the Drugs Differ From Each Other?

Somewhat, but the differences are small next to the differences in total weight lost. The network meta-analysis found that the agents producing the most weight loss, tirzepatide 15 mg and semaglutide 2.4 mg, were also the least effective at preserving lean mass in absolute terms. That is close to arithmetic: more total weight lost means more lean mass lost.

What matters for you is not which drug spares the most lean tissue on paper, but whether you are eating enough protein and loading your muscles while you take it. If you are comparing agents on other grounds, our head-to-head GLP-1 comparison covers efficacy and side effects.

Who Is Most at Risk?

Lean mass loss matters more for some people than others. Talk to your prescriber about monitoring if you fall into one of these groups:

Adults over 65. Age-related muscle loss is already underway, and it compounds with weight-loss-related loss. Fracture and fall risk is the practical concern.
People who already have low muscle mass or low strength. Sarcopenic obesity is common and frequently undiagnosed, as the SEMALEAN baseline rate of 49% illustrates.
People losing weight very fast. Faster loss generally means a worse fat-to-lean ratio.
People eating very little. These drugs cut appetite hard. It is entirely possible to end up at 700 calories a day and 40 g of protein without noticing.
People who are completely sedentary. Muscle that is not loaded is muscle the body treats as expendable.

What Actually Protects Muscle?

The evidence-backed list is short.

Protein at every meal. The 2025 joint advisory from The Obesity Society, the American College of Lifestyle Medicine, the American Society for Nutrition, and the Obesity Medicine Association names adequate protein intake and strength training as one of its eight priorities for people on GLP-1 therapy. It does not publish a single universal gram target, so ask a dietitian to set one for your body size and check that you are actually reaching it. The practical obstacle is that appetite suppression and nausea make protein the hardest macronutrient to get down, so it usually has to be planned first rather than last.

Resistance training two or more days a week. The Physical Activity Guidelines for Americans already recommend muscle-strengthening activity covering all major muscle groups on 2 or more days per week for every adult. On a GLP-1 drug that recommendation stops being optional. Loading the muscle is the signal that tells the body to keep it. Our guide to exercise on GLP-1 medications covers how to start if you have not trained before.

Not losing weight faster than you have to. Titrating up more slowly, if your prescriber agrees, generally means a better body-composition outcome.

Eating enough overall. Severe calorie restriction on top of an appetite-suppressing drug is the fastest path to losing lean tissue you wanted to keep.

Is a Muscle-Sparing Drug Coming?

Several are in development, and one has phase 2b data. In the BELIEVE trial, presented at the American Diabetes Association's 85th Scientific Sessions in June 2025, 507 adults with obesity were randomized across nine groups. At week 72, bimagrumab 30 mg/kg plus semaglutide 2.4 mg produced 22.1% weight loss, versus 15.7% for semaglutide alone. The headline number was the composition: 92.8% of the combination group's weight loss came from fat, against 71.8% for semaglutide alone. Semaglutide alone cut lean mass 7.4%; the combination cut it 2.9%.

Bimagrumab is an investigational antibody, not an approved drug, and phase 2b results are not approval. Treat it as a signal about where the field is heading, not as something to ask for at your next visit.

The Bottom Line

GLP-1 drugs do reduce lean mass, at roughly a quarter of total weight lost, which is the same proportion seen with placebo, with dieting, and with surgery. Strength does not necessarily fall with it: in the SEMALEAN cohort, grip strength went up and sarcopenic obesity became less common over a year of treatment. The risk is real but manageable, and it is concentrated in older adults, in people already low on muscle, and in people who lose weight fast while barely eating.

Protein and resistance training are the whole answer. If you take semaglutide specifically, our sister site ozempic.md covers muscle loss on Ozempic in drug-specific detail. And if you are weighing whether to stay on treatment long term, our article on what happens when you stop a GLP-1 drug covers what regain does to body composition.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider about treatment decisions.